FDA Approves New Treatment Option for Patients with ALS
"The FDA remains committed to facilitating the development of additional ALS treatments."
- "The FDA remains committed to facilitating the development of additional ALS treatments."
- ALS is a rare disease that attacks and kills the nerve cells that control voluntary muscles.
- ALS causes the nerves to lose the ability to activate specific muscles, which causes the muscles to become weak and leads to paralysis.
- The efficacy of Relyvrio for the treatment of ALS was demonstrated in a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.